# Fundamentals of lipoprotein(a) request and quantification in the clinical laboratory

## TL;DR

This paper reviews the importance of measuring lipoprotein(a) to assess cardiovascular risk and identify patients who may benefit from testing.

## Contribution

The paper provides updated evidence on Lp(a)'s role in cardiovascular risk and evaluates current testing methods and thresholds.

## Key findings

- Lp(a) is independently associated with increased risk of cardiovascular events.
- 10-30% of the global population has elevated Lp(a) levels above 50 mg/dL.
- New therapies for reducing Lp(a) have increased interest in its quantification.

## Abstract

Cardiovascular diseases keep being the leading cause of mortality in Spain. Efforts should be intensified to identify new risk factors that may contribute to increasing cardiovascular risk. Lipoprotein(a) (Lp(a)) has been associated with a higher risk for developing aortic valve stenosis, heart failure, ischemic stroke, ischemic heart disease and peripheral arterial disease. Hyperlipoproteinemia(a) is a common health problem. Between 10 and 30 % of the world population have Lp(a) values exceeding 50 mg/dL. The scientific evidence provided in the recent years confirms an independent association between Lp(a) and the risk for having an arteriosclerotic cardiovascular event. This finding, added to the emergence of new specific therapies for reducing Lp(a) has raised interest in the quantification of this lipoprotein. The objective of this paper was to perform a review of the evidence available to identify the patients who will benefit from undergoing Lp(a) testing and determine the recommended quantification methods, the desirable concentrations, and the role of Lp(a) determination in reclassifying the cardiovascular risk of patients.